Manipulation of the Complement System for Benefit in Sepsis

por Ward, Peter A., Guo, Ren-Feng, Riedemann, Niels C.
Publicado 2012

Adenovirus-Mediated In Vivo Silencing of Anaphylatoxin Receptor C5aR

por Sun, Lei, Gao, Hongwei, Sarma, Vidya J., Guo, Ren-feng, Ward, Peter A.
Publicado 2006

The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

por Vlaar, Alexander P. J., Lim, Endry H. T., de Bruin, Sanne, Rückinger, Simon, Pilz, Korinna, Brouwer, Matthijs C., Guo, Ren‐Feng, Heunks, Leo M. A., Busch, Matthias H., van Paassen, Pieter, Riedemann, Niels C., van de Beek, Diederik
Publicado 2022

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled tr...

por Vlaar, Alexander P J, de Bruin, Sanne, Busch, Matthias, Timmermans, Sjoerd A M E G, van Zeggeren, Ingeborg E, Koning, Rutger, ter Horst, Liora, Bulle, Esther B, van Baarle, Frank E H P, van de Poll, Marcel C G, Kemper, E Marleen, van der Horst, Iwan C C, Schultz, Marcus J, Horn, Janneke, Paulus, Frederique, Bos, Lieuwe D, Wiersinga, W Joost, Witzenrath, Martin, Rueckinger, Simon, Pilz, Korinna, Brouwer, Matthijs C, Guo, Ren-Feng, Heunks, Leo, van Paassen, Pieter, Riedemann, Niels C, van de Beek, Diederik
Publicado 2020